-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, FE00Lp2EN+bwt2v/r/EqM5Rc8o/wgdjbAnap4XyKhs8QfeZvk9FWjqYzZgiC4X55 sdLMO4oLEpvTFR0pKiIwXg== 0001467738-09-000010.txt : 20091113 0001467738-09-000010.hdr.sgml : 20091113 20091113093123 ACCESSION NUMBER: 0001467738-09-000010 CONFORMED SUBMISSION TYPE: SC 13D PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20091113 DATE AS OF CHANGE: 20091113 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Worden Andrew Barron CENTRAL INDEX KEY: 0001467738 FILING VALUES: FORM TYPE: SC 13D MAIL ADDRESS: STREET 1: 50 CENTRAL PARK SOUTH STREET 2: UNIT 34/35 CITY: NEW YORK STATE: NY ZIP: 10019 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Biostar Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001418133 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: MD FILING VALUES: FORM TYPE: SC 13D SEC ACT: 1934 Act SEC FILE NUMBER: 005-85087 FILM NUMBER: 091179346 BUSINESS ADDRESS: STREET 1: 11 EAST 86TH STREET, SUITE 19 B CITY: NEW YORK STATE: NY ZIP: 10028 BUSINESS PHONE: 1-646-623-6999 MAIL ADDRESS: STREET 1: 11 EAST 86TH STREET, SUITE 19 B CITY: NEW YORK STATE: NY ZIP: 10028 SC 13D 1 bspm13d.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Biostar Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 090678103 (CUSIP Number) Rebecca Baum 730 FIFTH AVENUE, 25TH FLOOR NEW YORK, NY 10019 212-359-0204 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) November 02, 2009 (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of 240.13d1(e), 240.13d-1(f) or 240.13d- 1(g), check the following box. [ ] Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See 240.13d-7 for other parties to whom copies are to be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP 090678103 13D 1 Name of Reporting Person Andrew Barron Worden I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds PF 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization United States Number of 7 Sole Voting Power Shares Owned 111,000 shares By Each 8 Shared Voting Power Reporting 257,000 Person With 9 Sole Dispositive Power 111,000 shares 10 Shared Dispositive Power 2,300,849 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 2,300,849 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 9.9%* 14 Type of Reporting Person IN *Represents the maximum amount the Reporting Persons could collectively own upon conversion or exercise of the Series B Preferred Stock and Warrants referenced in Item 5. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by Andrew Barron Worden, an individual (the "Reporting Person"), whose residence address is 50 Central Park South, Unit 34/35 New York, NY 10019. Andrew Barron Worden is the Managing Partner of Barron Capital Advisors LLC, a Delaware Limited Liability Company which is the General Partner to Barron Partners LP, a Delaware Limited Partnership, whose principal business is investing. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using personal funds. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person Barron Partners LP I.R.S. Identification No. of Above Person 43-1981699 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 250,000 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 250,000 shares 10 Shared Dispositive Power 0 11 Aggregate Amount Beneficially Owned by Each Reporting Person 250,000 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 1.1%* 14 Type of Reporting Person PN *The Reporting Person also owns warrants to purchase 118,765 of the Issuer's common stock shares for an exercise price of $3.00 per share and 500,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by Barron Partners LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 730 Fifth Avenue, 25th Floor, New York, NY 10019. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is Barron Capital Advisors LLC, a Delaware Limited Liability Company, (the "General Partner"). Andrew B. Worden is the managing member of the General Partner. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person Golden1177 LP I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 428,000 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 0 10 Shared Dispositive Power 428,000 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 428,000 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 1.8%* 14 Type of Reporting Person PN *The Reporting Person also owns Warrants to purchase 170,071 of the Issuer's Common Stock shares for an exercise price of $3.00 per share and 716,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by Golden1177 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is #500-1177 West Hastings Street, Vancouver BC V6E 2K3 Canada. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is Golden Properties, Ltd (the "General Partner"). Alex Lau is the Director of the General Partner. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person XWRT2 LP I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 24,500 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 0 10 Shared Dispositive Power 24,500 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 24,500 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 0.1%* 14 Type of Reporting Person PN *The Reporting Person also owns warrants to purchase 8,076 of the Issuer's common stock shares for an exercise price of $3.00 per share and 34,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by XWRT2 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 131 Laurel Grove Avenue Kentfield, CA 94904. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is Joseph Abrams(the "General Partner"), an individual. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person SBMT2 LP I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 24,400 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 0 10 Shared Dispositive Power 24,400 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 24,400 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 0.1%* 14 Type of Reporting Person PN *The Reporting Person also owns warrants to purchase 7,126 of the Issuer's common stock shares for an exercise price of $3.00 per share and 30,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by SBMT2 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 104 S. Pecos Street Midland, TX 79701. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is Carlton Beal Family Trust FBO Spencer Beal(the "General Partner"). Spencer Beal, an individual is the Trustee to the General Partner. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person Godfrey2468 LP I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 29,400 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 0 10 Shared Dispositive Power 29,400 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 29,400 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 0.1%* 14 Type of Reporting Person PN *The Reporting Person also owns warrants to purchase 9,501 of the Issuer's common stock shares for an exercise price of $3.00 per share and 40,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China.. Item 2. Identity and Background. This Statement is filed by Godfrey2468 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 128 Beachside Avenue Westport, CT 06880. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is Peter Godfrey, (the "General Partner"), an individual. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person LeeMadison9189 LP I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 23,850 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 0 10 Shared Dispositive Power 23,850 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 23,850 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 0.1%* 14 Type of Reporting Person PN *The Reporting Person also owns warrants to purchase 8,076 of the Issuer's common stock shares for an exercise price of $3.00 per share and 34,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons, , at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by LeeMadison9189 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 5871 East Carefree Mountain Drive Carefree, AZ 85377. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is The Robert M. Mayes and Laura L. Mayes Living Trust, (the "General Partner"). Robert M. Mayes, an individual, is the Trustee for the General Partner. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person RossPlan LP I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 132,700 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 0 10 Shared Dispositive Power 132,700 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 132,700 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 0.6%* 14 Type of Reporting Person PN *The Reporting Person also owns warrants to purchase 57,007 of the Issuer's common stock shares for an exercise price of $3.00 per share and 240,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by RossPlan LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 130 E. 65th Street New York, NY 10065. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is Santee River LLC, (the "General Partner"). Ross Pirastah is the managing member of the General Partner. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person Tibero2 LP I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 31,850 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 0 10 Shared Dispositive Power 31,850 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 31,850 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 0.1%* 14 Type of Reporting Person PN *The Reporting Person also owns warrants to purchase 11,876 of the Issuer's common stock shares for an exercise price of $3.00 per share and 50,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by Tibero2 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 29 Evergreen Way Wokingham, Berkshire RG41 4BX United Kingdom. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is Tim Robinson, (the "General Partner"), an individual. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person 2DanesRunnin LP I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 7,000 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 0 10 Shared Dispositive Power 7,000 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 7,000 shares 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] 13 Percent of Class Represented by Amount in Row (11) 0.0% 14 Type of Reporting Person PN Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by 2DanesRunnin LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 5016 Silver Lake Drive Plano, TX 75093. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is Higher Ground Investments, LP (the "General Partner"). The Canyons Climbing, LLC is the General Partner of Higher Ground Investments, LP. Robert A. Kaiser is the Managing Member of The Canyons Climbing, LLC. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person JBWA2 LP I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 37,500 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 0 shares 10 Shared Dispositive Power 37,500 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 37,500 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 0.2%* 14 Type of Reporting Person PN *The Reporting Person also owns warrants to purchase 14,252 of the Issuer's common stock shares for an exercise price of $3.00 per share and 60,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by JBWA2 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 650 Bellevue Way NE Suite 3704 Bellevue, WA 98004. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is Jim Jensen (the "General Partner"), an individual. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person Kaufman2 LP I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 67,000 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 0 shares 10 Shared Dispositive Power 67,000 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 67,000 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 0.3%* 14 Type of Reporting Person PN *The Reporting Person also owns warrants to purchase 23,753 of the Issuer's common stock shares for an exercise price of $3.00 per share and 100,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by Kaufman2 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 127 W. 69th Street New York, Ny 10023. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is Daniel Kaufman (the "General Partner"), an individual. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person Fernando Liu I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds PF 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization People's Republic of China Number of 7 Sole Voting Power Shares Owned 8,600 shares By Each 8 Shared Voting Power Reporting Person With 9 Sole Dispositive Power 10 Shared Dispositive Power 8,600 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 8,600 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [x ] 13 Percent of Class Represented by Amount in Row (11) 0.0%* 14 Type of Reporting Person IN *The Reporting Person also owns warrants to purchase 2,375 of the Issuer's common stock shares for an exercise price of $3.00 per share and 10,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by Fernando Liu whose residence address is Room 302, Unit 18, 299 HuXin Road, MinHang District Shanghai 201101 China. The Reporting Person is principally employed as a Regional Manager by Barron Partners Asia whose business address is Suite 1201, Tower 1, Hyundai Plaza,369 XianXia Road, ChangNing District, Shanghai, PRC 200336. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using personal funds. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person SAS148 LP I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power Shares Owned 7,000 shares By Each 8 Shared Voting Power Reporting 0 Person With 9 Sole Dispositive Power 7,000 shares 10 Shared Dispositive Power 0 11 Aggregate Amount Beneficially Owned by Each Reporting Person 7,000 shares 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ ] 13 Percent of Class Represented by Amount in Row (11) 0.0% 14 Type of Reporting Person PN Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by SAS148 LP, a Delaware Limited Partnership (the "Reporting Person"), whose business address is 450 Sansome Street, 14th Floor, San Francisco, CA 94111. The Reporting Person is principally engaged in making investments. The General Partner of the Reporting Person is Andrew Barron Worden (the "General Partner"), an individual. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using working capital. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. 1 Name of Reporting Person Olga Filippova I.R.S. Identification No. of Above Person 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds PF 5 Check Box if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization People's Republic of China Number of 7 Sole Voting Power Shares Owned 3,000 shares By Each 8 Shared Voting Power Reporting Person With 9 Sole Dispositive Power 10 Shared Dispositive Power 3,000 shares 11 Aggregate Amount Beneficially Owned by Each Reporting Person 3,000 shares* 12 Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares [ x ] 13 Percent of Class Represented by Amount in Row (11) 0.0%* 14 Type of Reporting Person IN *The Reporting Person also owns warrants to purchase 1,425 of the Issuer's common stock shares for an exercise price of $3.00 per share and 6,000 of the Issuer's Series B Convertible Preferred Stock, therefore beneficial ownership could increase to an amount equal to 9.9% minus the percentage ownership of all other Reporting Persons at the time of exercise or conversion. Item 1. Security and Issuer. This statement relates to shares of common stock, par value $0.001 per share, (the "Common Stock") of Biostar Pharmaceuticals, Inc. a Maryland corporation (the "Company") having its principal executive offices at No. 588 Shiji Avenue, Xiangyang City, Shaanxi Province, The People's Republic of China. Item 2. Identity and Background. This Statement is filed by Olga Filippova whose residence address is 3 Havelock Terrace Dublin 4, Ireland. The Reporting Person is principally employed as a Principal by Barron Partners, LP whose business address is 730 Fifth Avenue, 25th floor New York, NY 10019. The Reporting Person has granted trading authorization of the shares of Common Stock to Andrew Barron Worden and shares dispositive power of the shares of Common Stock with Andrew Barron Worden. During the last five years, to the best knowledge of the Reporting Person, neither the Reporting Person nor any controlling person of the Reporting Person has (i) been convicted in a criminal proceeding, or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or State securities laws or finding any violation with respect to such laws. Item 3. Source and Amount of Funds or Other Consideration. All purchases of the Common Stock of the Company were made using personal funds. Item 4. Purpose of Transaction. All Issuer's securities owned by the Reporting Person have been acquired by the Reporting Person for investment purposes only. Item 5. Interest in Securities of the Issuer.- (a) On November 2, 2009, the Reporting Persons, excluding 2DanesRunnin LP and SAS148 LP, purchased an aggregate number of 1,000,000 Common Stock shares of the Issuer at a price of $1.75 per share in a private transaction. Also, on November 2, 2009, the Reporting Persons, excluding 2DanesRunnin LP and SAS148 LP, purchased an aggregate number of 2,000,0000 shares of the Issuer's Series B Preferred Stock convertible into 2,000,000 shares of the Issuer's Common Stock and Warrants to purchase 475,059 of the Issuer's Common Stock shares with an exercise price of $3.00 per share in a private offering by the Issuer. The Reporting Persons, excluding 2DanesRunnin LP and SAS148 LP, have contractually agreed that they shall not have the right to exercise the Warrants or convert the Preferred Stock purchased on November 2nd, 2009 from the Issuer to the extent that after giving effect to such conversion, the Reporting Persons would collectively beneficially own in excess of 9.9% of the number of shares of the Common Stock outstanding immediately after giving effect to such conversion and/or exercise. As a result of this 9.9% limitation, the Reporting Persons will not have more than 9.9% of the voting power of the Issuer. The Issuer's securities owned by the Reporting Persons as of November 2, 2009, represented approximately 5.1% of the issued and outstanding shares of the Issuer's common stock. The aggregate number of Issuer's securities owned by the Reporting Persons as of the date of this filing, represents approximately 5.1% of the issued and outstanding shares of the Issuer's common stock. (b) Each of the Reporting Persons has sole power to vote the shares of the Issuer's common stock owned of record by it and shared power to dispose of the shares of Issuer's Common Stock beneficially owned by it; except for the Reporting Person, Andrew Barron Worden, who also has shared power to vote the shares owned of record by Reporting Persons, Barron Partners, LP and SAS148 LP and shared power to dispose of the shares beneficially owned by each of the Reporting Persons. (c) In addition to Item 5(a), in the past sixty days, the Reporting Persons bought an aggregate of 313,800 shares of the Common Stock in open market transactions at prices ranging from $1.72 to $1.90 per share. Additionally, the Reporting Persons sold an aggregate of 128,000 shares of the Common Stock in open market transactions at prices ranging from $2.06 to $2.47 per share. Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer. The Reporting Persons are filing jointly because each has severally granted trading authorization of the Issuer's shares of Common Stock to Andrew Barron Worden and therefore shares dispositive power with Andrew Barron Worden. Item 7. Material to be Filed as Exhibits. Not applicable. SIGNATURE1 After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: November 12, 2009 /s/ ANDREW BARRON WORDEN - -------------------- Signature Andrew Worden -----END PRIVACY-ENHANCED MESSAGE-----